Jump to content

Dextromethorphan: Difference between revisions

From Pharmacopedia
[checked revision][pending revision]
Pharmacopedia: add <pharmaInteractions/>
home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean)
 
(3 intermediate revisions by 3 users not shown)
Line 21: Line 21:
| indications        =  
| indications        =  
| dosing            =  
| dosing            =  
<titration slug="erowid-dose-oral" author="erowid-claude"
title="Oral dose ladder (Erowid, HBr salt)">
Erowid's dosage documentation for oral dextromethorphan hydrobromide<ref
name="erowid-dxm-dose">Erowid. DXM Dosage. Erowid.org.
https://www.erowid.org/chemicals/dxm/dxm_dose.shtml.
Accessed 2026-05-26.</ref> reports the following tiers:
* '''Light:''' 100-200 mg
* '''Common:''' 200-400 mg
* '''Strong:''' 300-600 mg
* '''Heavy:''' 600-1,500 mg
Threshold not characterized. Duration 4 to 8 hours for standard HBr
formulations; 6 to 12 hours for extended-release polistirex
formulations. Erowid notes that doses are affected significantly by
body weight and recommends conservative starting amounts. A critical
harm note: many OTC formulations containing DXM also include
acetaminophen, chlorpheniramine maleate (CPM), guaifenesin, or other
active ingredients that become dangerous at the doses required for
psychoactive DXM effects; use of single-ingredient preparations is
essential for harm reduction.
</titration>
| effects            =  
| effects            =  
| interactions      = <pharmaInteractions/>
| interactions      = <pharmaInteractions/>
Line 31: Line 53:
}}
}}


[[Category:Psychedelics]]
[[Category:Dissociatives]]
[[Category:Dissociatives]]
[[Category:Morphinans]]
[[Category:Dissociative Anesthetics]]
[[Category:NMDA receptor antagonists]]

Latest revision as of 17:24, 26 May 2026

Dissociative
Dextromethorphan
DXM

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

Oral dose ladder (Erowid, HBr salt)0
Erowid's dosage documentation for oral dextromethorphan hydrobromide[1] reports the following tiers:
  • Light: 100-200 mg
  • Common: 200-400 mg
  • Strong: 300-600 mg
  • Heavy: 600-1,500 mg

Threshold not characterized. Duration 4 to 8 hours for standard HBr formulations; 6 to 12 hours for extended-release polistirex formulations. Erowid notes that doses are affected significantly by body weight and recommends conservative starting amounts. A critical harm note: many OTC formulations containing DXM also include acetaminophen, chlorpheniramine maleate (CPM), guaifenesin, or other active ingredients that become dangerous at the doses required for psychoactive DXM effects; use of single-ingredient preparations is

essential for harm reduction.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions6 edges
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 substrate major Primary 80 / 100
FDA Drug Interactions Table: sensitive index substrate of CYP2D6.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Quinidine pk raises via CYP2D6 Inferred 76 / 100
Quinidine inhibits CYP2D6 (inhibitor_strong, intensity 95); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Fluoxetine pk raises via CYP2D6 Inferred 72 / 100
Fluoxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Paroxetine pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Bupropion pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Mirabegron pk raises via CYP2D6 Inferred 44 / 100
Mirabegron inhibits CYP2D6 (inhibitor_moderate, intensity 55); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
Inferred via Enzyme:CYP2D6 (exposure raised)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Dissociative
Common uses
Pharmacy
Pharmacology
Purported mechanism
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor
  1. Erowid. DXM Dosage. Erowid.org. https://www.erowid.org/chemicals/dxm/dxm_dose.shtml. Accessed 2026-05-26.